Vor Biopharma’s (VOR) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a report issued on Friday,Benzinga reports. Oppenheimer currently has a $8.00 price objective on the stock.

A number of other equities analysts have also recently commented on VOR. HC Wainwright reduced their price objective on shares of Vor Biopharma from $17.50 to $13.00 and set a “buy” rating for the company in a research report on Friday. Stifel Nicolaus reduced their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday. Wedbush reissued an “outperform” rating and issued a $7.00 price target on shares of Vor Biopharma in a report on Thursday. Finally, JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma has a consensus rating of “Buy” and an average price target of $8.86.

Vor Biopharma Stock Up 2.1 %

VOR opened at $0.87 on Friday. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $2.43. The business has a 50 day moving average of $1.22 and a 200-day moving average of $1.01. The stock has a market cap of $59.75 million, a price-to-earnings ratio of -0.53 and a beta of -0.40.

Institutional Trading of Vor Biopharma

A number of institutional investors have recently bought and sold shares of the business. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Vor Biopharma in the fourth quarter valued at approximately $33,000. Virtu Financial LLC acquired a new position in Vor Biopharma in the 4th quarter valued at $60,000. XTX Topco Ltd bought a new stake in shares of Vor Biopharma during the 4th quarter valued at $80,000. Trustees of Columbia University in the City of New York acquired a new stake in shares of Vor Biopharma during the 4th quarter worth $102,000. Finally, Northern Trust Corp grew its holdings in shares of Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after purchasing an additional 44,252 shares in the last quarter. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.